Cited by 854Bone health and treatmentsAngiogenesis and VEGF in CancerBone Metabolism and Diseases

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Wood, Jeanette, Bonjean, Karine, Ruetz, Stephan, Bellahcène, Akeila, Devy, Laetitia, Foidart, Jean Michel, Castronovo, Vincent, Green, Jonathan R.·2002·The Journal of Pharmacology and Experimental Therapeutics

DOI 10.1124/jpet.102.035295

Open this paper in CoChat — free account

Abstract

Bisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with tumor-induced osteolysis. We now show that zoledronic acid, a new generation bisphosphonate with a heterocyclic imidazole substituent, is also a potent inhibitor of angiogenesis. In vitro, zoledronic acid inhibits proliferation of human endothelial cells stimulated with fetal calf serum, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (IC(50) values 4.1, 4.2, and 6.9 microM, respectively), and modulates endothelial cell adhesion and migration. In cultured aortic rings and in the chicken egg chorioallantoic membrane assay, zoledronic acid reduces vessel sprouting. When administered systemically to mice, zoledronic acid potently inhibits the angiogenesis induced by subcutaneous implants impregnated with bFGF [ED(50), 3 microg/kg (7.5 nmol/kg) s.c.]. These findings indicate that zoledronic acid has marked antiangiogenic properties that could augment its efficacy in the treatment of malignant bone disease and extend its potential clinical use to other diseases with an angiogenic component.

Integrity signals

Registry

Crossref · 10.1124/jpet.102.035295

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization
Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., & Isner, J. M. (1999) · Circulation Research · doi:10.1161/01.res.85.3.221 · Cited by 3,263
Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,109
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D., Mundy, G. R., & Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,039
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844
Self-citation
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I., Solomayer, E., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D. R., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices.
Montesano, R., Orci, L., & VASSALLI, P. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.97.5.1648 · Cited by 647
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Berenson, J. R., Lichtenstein, A. K., Porter, L., Dimopoulos, M. A., Bordoni, R. E., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 645

Flagged first, then by citations

Show all 33 references

1 of the 33 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Boissier, 2020, Zoledronic acid inhibits in vivo experimental angiogenesis (abstract B3)., Bone, 30, 38S
Bonjean, 2002, Zoledronic acid inhibits human endothelial cell adhesion to vitronectin and selectively alters the expression of extracellular matrix cell surface receptors (abstract B4)., Bone, 30, 38S

Sorted by citations

Items 201–300 of 845

Bisphosphonates: new indications and methods of administration
Reid, I. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00014 · Cited by 60
Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm
Malden, N., Beltes, C., & Lopes, V. (2009) · BDJ · doi:10.1038/sj.bdj.2009.5 · Cited by 58
Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates
Santini, D., Caraglia, M., Vincenzi, B., Holen, I., Scarpa, S., Budillon, A., & Tonini, G. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0520 · Cited by 58
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
Fred Saad, C., & Lipton, A. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05740.x · Cited by 57
Dental Endosseous Implants in Patients on Bisphosphonate Therapy
Scully, C. M., Madrid, C., & Sebastián, J. V. B. (2006) · Implant Dentistry · doi:10.1097/01.id.0000236120.22719.02 · Cited by 57
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
Sanna, G., Preda, L., Bruschini, R., Rocca, M. C., Ferretti, S., Adamoli, L., Verri, E., Franceschelli, L., Goldhirsch, A., & Nolè, F. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl163 · Cited by 57
Perioperative Antibiotic Regimen in Rats Treated With Pamidronate Plus Dexamethasone and Subjected to Dental Extraction: A Study of the Changes in the Jaws
López‐Jornet, P., Camacho‐Alonso, F., Martínez-Cánovas, A., Molina‐Miñano, F., García, F. J., & Vicente‐Ortega, V. (2011) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2011.02.059 · Cited by 56
Knowledge, Practices, and Opinions of Ontario Dentists When Treating Patients Receiving Bisphosphonates
AlHussain, A., Peel, S. A. F., Dempster, L. J., Clokie, C. M. L., & Azarpazhooh, A. (2015) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.12.040 · Cited by 56
Anti-tumour activity of zoledronic acid
Clézardin, P. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.09.002 · Cited by 56
Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?
Klingelhöffer, C., Klingelhöffer, M., Müller, S., Ettl, T., & Wahlmann, U. (2016) · Dentomaxillofacial Radiology · doi:10.1259/dmfr.20160065 · Cited by 55
Osteomyelitis of the Jaws: Definition and Classification
Baltensperger, M. M., & Eyrich, G. (2008) · Springer eBooks · doi:10.1007/978-3-540-28766-7_2 · Cited by 55
Breast cancer bone metastasis and current small therapeutics
Cicek, M., & Oursler, M. J. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9035-x · Cited by 55
Extraction socket healing in rats treated with bisphosphonate: Animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients
Ali-Erdem, M., Burak-Cankaya, A., Cemil-Isler, S., Demircan, S., Soluk, M., Kasapoğlu, Ç., & Oral, C. K. (2011) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.17150 · Cited by 54
An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats
López‐Jornet, P., Camacho‐Alonso, F., Molina‐Miñano, F., García, F. J., & Vicente‐Ortega, V. (2010) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2010.00927.x · Cited by 53
Pathophysiology of BRONJ: Drug‐related osteoclastic disease of the jaw
Ikebe, T. (2012) · Oral Science International · doi:10.1016/s1348-8643(12)00045-6 · Cited by 54
Zoledronic acid: an unending tale for an antiresorptive agent
Caraglia, M., Marra, M., Naviglio, S., Botti, G., Addeo, R., & Abbruzzese, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903485664 · Cited by 53
Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws
Boff, R. C., Salum, F. G., de Figueiredo, M. A. Z., & Cherubini, K. (2014) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2014.05.002 · Cited by 52
Effects of Risedronate on Alveolar Bone Loss and Angiogenesis: A Stereologic Study in Rats
Cetinkaya, B. O., Keleș, G. Ç., Ayas, B., & Gürgör, P. N. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080041 · Cited by 54
Influence of bisphosphonates in orthodontic therapy: Systematic review
Iglesias‐Linares, A., Yáñez-Vico, R.-M., Solano-Reina, E., Torrés-Lagares, D., & González‐Moles, M. Á. (2010) · Journal of Dentistry · doi:10.1016/j.jdent.2010.05.012 · Cited by 51
The use of bisphosphonates in cancer patients
Wu, S., Dahut, W. L., & Gulley, J. L. (2007) · Acta Oncologica · doi:10.1080/02841860701233435 · Cited by 51
A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture
Cross, M. B., Nam, D., van der Meulen, M. C. H., & Bostrom, M. P. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b7.28778 · Cited by 51
Hyperbaric oxygen therapy and osteonecrosis
Ceponis, P. J. M., Keilman, C. G., Guerry, C., & Freiberger, J. J. (2016) · Oral Diseases · doi:10.1111/odi.12489 · Cited by 55
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis
Ortega, C., Montemurro, F., Faggiuolo, R., Vormola, R., Nanni, D., Goia, F., Gilardino, M. O., & Aglietta, M. (2007) · Acta Oncologica · doi:10.1080/02841860601185917 · Cited by 51
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment
Dickinson, M. J., Prince, H. M., Kirsa, S. W., Zannettino, A. C. W., Gibbs, S. D., Mileshkin, L., O’Grady, J. S., Seymour, J. F., Szer, J., Horvath, N., et al. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01824.x · Cited by 51
Bisphosphonates and jaw osteonecrosis: The UAMS experience
Clarke, B. M., Boyette, J. R., Vural, E. A., Suen, J. Y., Anaissie, E. J., & Stack, B. C. (2007) · Otolaryngology · doi:10.1016/j.otohns.2006.11.008 · Cited by 51
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
Santini, D., Vincenzi, B., Hannon, R. A., Brown, J. E., Dicuonzo, G., Angeletti, S., Cesa, A. L., Coleman, R. L., Tonini, G., Budillon, A., et al. (2006) · Oncology Reports · doi:10.3892/or.15.5.1351 · Cited by 51
Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab
Niibe, K., Ouchi, T., Iwasaki, R., Nakagawa, T., & Horie, N. (2014) · Journal of Prosthodontic Research · doi:10.1016/j.jpor.2014.08.001 · Cited by 50
Atypical femoral fracture in a patient treated with denosumab
Khow, K. S. F., & Yong, T. Y. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0606-6 · Cited by 50
Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris
Maurer, P., Sandulescu, T., Kriwalsky, M. S., Rashad, A., Hollstein, S., Stricker, I., Hölzle, F., & Kunkel, M. (2010) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2010.11.006 · Cited by 50
Treatment of Hypertrophic Osteoarthropathy with Zoledronic Acid: Case Report and Review of the Literature
Jayakar, B. A., Abelson, A. G., & Yao, Q. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.01.007 · Cited by 49
Oral Bisphosphonates and Improved Survival of Breast Cancer
Rennert, G., Pinchev, M., Gronich, N., Saliba, W., Flugelman, A. A., Lavi, I., Goldberg, H., Fried, G., Steiner, M., Bitterman, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0547 · Cited by 49
Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma
Choi, W.-S., Lee, J., Yoon, H.-J., Min, C., & Lee, S. H. (2017) · Maxillofacial Plastic and Reconstructive Surgery · doi:10.1186/s40902-016-0099-4 · Cited by 49
Bisphosphonates Induce Apoptosis of Circulating Endothelial Cells in Multiple Myeloma Patients and in Subjects with Bisphosphonate-Induced Osteonecrosis of the Jaws
Allegra, A., Alonci, A., Penna, G., Granata, A., Siniscalchi, E. N., Oteri, G., Loddo, S., Teti, D. V., Cicciù, D., Ponte, F. S. D., et al. (2010) · Acta Haematologica · doi:10.1159/000313787 · Cited by 49
Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion
Stathopoulos, G. T., Moschos, C., Loutrari, H. V., Kollintza, A., Psallidas, I., Karabela, S. P., Magkouta, S., Zhou, Z., Papiris, S. A., Roussos, C., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1513oc · Cited by 49
Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model
Hashimoto, K., Morishige, K.-I., Sawada, K., Tahara, M., Kawagishi, R., Ikebuchi, Y., Sakata, M., Tasaka, K., & Murata, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.540.65.2 · Cited by 49
Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study
Moreira, M. S., Katayama, E., Bombana, A. C., & Marques, M. M. (2005) · Dental Traumatology · doi:10.1111/j.1600-9657.2005.00370.x · Cited by 49
Bisphosphonates – A Word of Caution
Robinson, N., & Yeo, J. (2004) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v33n4p48s · Cited by 49
Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma
Diego, R., D’Orto, O., Pagani, D., Agazzi, A., Marzano, U. G., Troletti, G. D., Fontanella, W., & Pignataro, L. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.09.022 · Cited by 48
Parathyroid Hormone 1-84 Targets Bone Vascular Structure and Perfusion in Mice: Impacts of Its Administration Regimen and of Ovariectomy
Roche, B., Vanden‐Bossche, A., Malaval, L., Normand, M., Jannot, M., Chaux, R., Vico, L., & Lafage‐Proust, M. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2191 · Cited by 47
Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A LongitudinalIn vivoStudy
Bäuerle, T., Merz, M., Komljenovic, D., Zwick, S., & Semmler, W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2932 · Cited by 47
Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw
de Lima, P. B., Brasil, V. L. M., de Castro, J. F. L., Ramos‐Perez, F. M. D. M., Alves, F. A., Pontual, M. L. D. A., & Pérez, D. E. D. C. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2689-6 · Cited by 47
Bisphosphonate osteonecrosis: a protocol for surgical management
Markose, G., Mackenzie, F. R., Currie, W. J. R., & Hislop, W. S. (2009) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2009.01.007 · Cited by 47
Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Poznak, C. H. V., & Estilo, C. L. (2006) · PubMed · Cited by 47
ZOLEDRONIC ACID IS EFFECTIVE IN PREVENTING AND DELAYING SKELETAL EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO GENITOURINARY CANCERS
Fred Saad, C., & Lipton, A. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06279_7.x · Cited by 47
The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies
Zhang, H., Liesveld, J. L., Calvi, L. M., Lipe, B. C., Xing, L., Becker, M. W., Schwarz, E. M., & Yeh, S.-C. A. (2023) · Bone Research · doi:10.1038/s41413-023-00249-w · Cited by 48
Therapeutic targeting of osteoclast function and pathways
Broadhead, M. L., Clark, J. C. M., Dass, C. R., Choong, P., & Myers, D. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.546351 · Cited by 46
A Retrospective Clinical and Radiographic Study on Healing of Periradicular Lesions in Patients Taking Oral Bisphosphonates
Hsiao, A., GLICKMAN, G. N., & He, J. (2009) · Journal of Endodontics · doi:10.1016/j.joen.2009.07.020 · Cited by 46
Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates
Wilson, C., Holen, I., & Coleman, R. E. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.007 · Cited by 46
Treatment for Myeloma Bone Disease
Yeh, H., & Berenson, J. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0681 · Cited by 46
Angiogenesis in human cancer: implications in cancer therapy
Bamias, A., & Dimopoulos, M. A. (2003) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2003.10.003 · Cited by 46
Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease
Bobba, R. S., BEATTIE, K. A., Parkinson, B., Kumbhare, D. A., & Adachi, J. D. (2006) · Drug Safety · doi:10.2165/00002018-200629120-00005 · Cited by 47
Pleiotropic effects of bisphosphonates on osteosarcoma
Ohba, T., Cates, J., Cole, H., Slosky, D., Haro, H., Ichikawa, J., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Bone · doi:10.1016/j.bone.2014.03.005 · Cited by 45
The anti-tumor potential of zoledronic acid
Croucher, P. I., Jagdev, S., & Coleman, R. E. (2003) · The Breast · doi:10.1016/s0960-9776(03)80161-3 · Cited by 45
Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients
Lescaille, G., Coudert, A. E., Baaroun, V., Ostertag, A., Charpentier, E., Javelot, M.-J., Toledo, R., Goudot, P., Azérad, J., Berdal, A., et al. (2013) · Bone · doi:10.1016/j.bone.2013.10.002 · Cited by 44
Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts
Zafar, S., Coates, D. E., Cullinan, M. P., Drummond, B. K., Milne, T. J., & Seymour, G. J. (2016) · Clinical Oral Investigations · doi:10.1007/s00784-015-1706-y · Cited by 44
Treatment Considerations for the Management of Fibrodysplasia Ossificans Progressiva
Glaser, D. L., & Kaplan, F. S. (2005) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:3:3-4:243 · Cited by 44
Microvascular Endothelial Cell Responses in vitro and in vivo: Modulation by Zoledronic Acid and Paclitaxel?
Michailidou, M., Brown, H. K., Lefley, D. V., Evans, A., Cross, S. S., Coleman, R. E., Brown, N. J., & Holen, I. (2010) · Journal of Vascular Research · doi:10.1159/000313876 · Cited by 44
Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes
Ohnuki, H., Izumi, K., Terada, M., Saito, T., Kato, H., Suzuki, A., Kawano, Y., Nozawa‐Inoue, K., Takagi, R., & Maeda, T. (2011) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2011.11.015 · Cited by 43
Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
Verron, É., & Bouler, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.08.010 · Cited by 43
Tetracycline-Guided Debridement and Cone Beam Computed Tomography for the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw: A Technical Note
Fleisher, K. E., Doty, S. B., Kottal, S., Phelan, J. A., Norman, R. G., & Glickman, R. S. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.07.021 · Cited by 43
Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid
Cafro, A. M., Barbarano, L., Nosari, A., D’Avanzo, G., Nichelatti, M., Bibas, M., Gaglioti, D., Taroni, A., Riva, F. M. G., D’Avanzo, G., et al. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.013 · Cited by 43
Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice
Tuomela, J. M., Valta, M. P., Väänänen, K., & Härkönen, P. L. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-81 · Cited by 43
Alveolar bone and the bisphosphonates
Cheng, A., Daly, C., Logan, R., Stein, B. N., & Goss, A. N. (2009) · Australian Dental Journal · doi:10.1111/j.1834-7819.2009.01143.x · Cited by 43
Synthesis of 1‐Hydroxymethylene‐1,1‐bis(phosphonic acids) from Acid Anhydrides: Preparation of a New Cyclic 1‐Acyloxymethylene‐1,1‐bis(phosphonic acid)
Guénin, E., Degache, E., Liquier, J., & Lecouvey, M. (2004) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200400053 · Cited by 43
Tooth Extractions in High-Risk Patients Under Bisphosphonate Therapy and Previously Affected With Osteonecrosis of the Jaws
Vescovi, P., Giovannacci, I., Merigo, E., Meleti, M., Manfredi, M., Fornaini, C., & Nammour, S. (2015) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000001665 · Cited by 43
Hyperbaric Oxygen in Addition to Antibiotic Therapy Is Effective for Bisphosphonate-Induced Osteonecrosis of the Jaw in a Patient with Multiple Myeloma
Shimura, K., Shimazaki, C., Taniguchi, K., Akamatsu, S., Okamoto, M., Uchida, R., Nomura, K.-I., Inaba, T., Horiike, S., Kanamura, N., et al. (2006) · International Journal of Hematology · doi:10.1532/ijh97.06110 · Cited by 43
Bisphosphonate-Related Osteonecrosis of the Jaw and Oral Microbiome: Clinical Risk Factors, Pathophysiology and Treatment Options
Jelin-Uhlig, S., Weigel, M., Ott, B., Imirzalioglu, C., Howaldt, H., Böttger, S., & Hain, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158053 · Cited by 42
The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches
Soki, F. N., Li, X., Berry, J. E., Koh, A. J., Sinder, B. P., Xu, Q., Kozloff, K. M., Taichman, R. S., & McCauley, L. K. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24301 · Cited by 42
Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature
Rustemeyer, J., & Bremerich, A. (2009) · Clinical Oral Investigations · doi:10.1007/s00784-009-0294-0 · Cited by 42
Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management
Wimalawansa, S. J. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.4.491 · Cited by 42
Bisphosphonates in breast cancer
Mathew, A., & Brufsky, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28965 · Cited by 41
Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site
Liu, Y.-L., Lindert, S., Zhu, W., Wang, K., McCammon, J. A., & Oldfield, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409061111 · Cited by 41
A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy
Iwata, K., Mashiba, T., Hitora, T., Yamagami, Y., & Yamamoto, T. (2014) · Bone · doi:10.1016/j.bone.2014.04.012 · Cited by 41
Zoledronic acid
Coleman, R. E., Burkinshaw, R., Winter, M. C., Neville-Webbe, H. L., Lester, J., Woodward, E., & Brown, J. E. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540387 · Cited by 41
Use of bisphosphonates for the treatment of stress fractures in athletes
Shima, Y., Engebretsen, L., Iwasa, J., Kitaoka, K., & Tomita, K. (2008) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1007/s00167-008-0673-0 · Cited by 41
Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies
Jiang, A., Zhang, Z., Qiu, X., & Guo, Q. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03653-7 · Cited by 45
Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts
Zafar, S., Coates, D. E., Cullinan, M. P., Drummond, B. K., Milne, T. J., & Seymour, G. J. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12181 · Cited by 40
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Mitri, Z. I., Nanda, R., Blackwell, K., Costelloe, C. M., Hood, I., Wei, C., Brewster, A. M., Ibrahim, N. K., Koenig, K. B., Hortobágyi, G. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2845 · Cited by 44
Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Ruiz, M. E., Gantner, M. E., & Talevi, A. (2013) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574891x113089990038 · Cited by 41
Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study
Chiang, C.-H., Huang, C., Chan, W., Huang, P., Chen, T., Chung, C., Lin, S., Chen, J., & Leu, H. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1645 · Cited by 39
Periprosthetic bone loss: diagnostic and therapeutic approaches
Cavalli, L., & Brandi, M. L. (2013) · F1000Research · doi:10.12688/f1000research.2-266.v2 · Cited by 39
Pharmacology of bisphosphonates in pain
Tzschentke, T. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14799 · Cited by 40
Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw
Sharma, D., Hamlet, S. M., Vaquette, C., Petcu, E. B., Ramamurthy, P., & Ivanovski, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-02637-w · Cited by 39
A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis
Scheper, M., Chaisuparat, R., Cullen, K. J., & Meiller, T. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-6 · Cited by 39
Molecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study
Juillard, A., Falgayrac, G., Cortet, B., Vieillard, M.-H., Azaroual, N., Hornez, J., & Penel, G. (2010) · Bone · doi:10.1016/j.bone.2010.07.018 · Cited by 38
Medication-Related Osteonecrosis of the Jaw—2014 Update
Ruggiero, S. L., Dodson, T. B., Goodday, R. H. B., Aghaloo, T. L., & Mehrotra, B. (2014) · Cited by 38
The Effect of Platelet-Rich Fibrin Membrane in Surgical Therapy of Medication-Related Osteonecrosis of the Jaw
Szentpéteri, S., Schmidt, L., Restár, L., Csaki, G., Szabó, G., & Vaszilkó, M. (2019) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2019.12.008 · Cited by 38
Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner
McLeod, N. M. H., Davies, B., & Brennan, P. A. (2007) · BDJ · doi:10.1038/bdj.2007.1065 · Cited by 38
Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.
CAPSONI, F., Longhi, M., & Weinstein, R. L. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2050 · Cited by 38
Bisphosphonates and Cancer: What Opportunities from Nanotechnology?
Rosa, G. D., Misso, G., Salzano, G., & Caraglia, M. (2013) · Journal of Drug Delivery · doi:10.1155/2013/637976 · Cited by 39
Bisphosphonate-Associated Osteonecrosis of the Jaw
Treister, N. S., & Woo, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmicm055784 · Cited by 37
Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis
Tubiana-Hulin, M., Spielmann, M., Roux, C., Campone, M., Zelek, L. H., Gligorov, J., Samson, J., Lesclous, P., Larédo, J.-D., & Namer, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.10.009 · Cited by 37
Anticancer Properties of Zoledronic Acid
Green, J., & Lipton, A. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.512598 · Cited by 37
Self-citation
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Soltau, J., Zirrgiebel, U., Esser, N., Schächtele, C., Totzke, F., Unger, C., Merfort, I., & Drevs, J. (2008) · PubMed · Cited by 36
Optimising Antiresorptive Therapies in Postmenopausal Women
Karsdal, M. A., Qvist, P., Christiansen, C., & Tank, L. S. B. (2006) · Drugs · doi:10.2165/00003495-200666150-00002 · Cited by 36
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells
Muraro, M., Mereuta, O. M., Carraro, F., Madon, E., & Fagioli, F. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2007.11.005 · Cited by 38
Bisphosphonate-related osteonecrosis of the jaws (BRONJ)
Beninati, F., Pruneti, R., & Ficarra, G. (2013) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.18076 · Cited by 36
Myeloma bone disease and treatment options
Yeh, H., & Berenson, J. R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.035 · Cited by 36
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Dass, C. R., Tran, T. M. N., & Choong, P. (2007) · Journal of Dental Research · doi:10.1177/154405910708601005 · Cited by 35
Bisphosphonates and dental implants: current problems.
Flichy‐Fernández, A. J., Balaguer‐Martínez, J., Diago, M. P., & Sebastián, J. V. B. (2009) · PubMed · Cited by 35

Authors: Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R.
Affiliations: Novartis (Switzerland) (CH)
University of Liège (BE)
ORCID: Bellahcène, Akeila
Venue: The Journal of Pharmacology and Experimental Therapeutics
Publisher: Elsevier BV
Published: 2002-01
Volume: 302
Issue: 3
Pages: 1055-1061
ISSN: 0022-3565 (ISSN-L)
DOI: 10.1124/jpet.102.035295
OpenAlex: W2144860907
Cited by: 854
References: 33
Citations by year: 2026: 13 · 2025: 17 · 2024: 14 · 2023: 20 · 2022: 17 · 2021: 18 · 2020: 22 · 2019: 34 · 2018: 23 · 2017: 20 · 2016: 24 · 2015: 38 · 2014: 46 · 2013: 44 · 2012: 36
FWCI: 14.78
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
PubMed (publishedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: zoledronic acid, bisphosphonates, antiangiogenic activity, angiogenesis inhibition, endothelial cell proliferation, basic fibroblast growth factor, vascular endothelial growth factor, endothelial cell adhesion, endothelial cell migration, tumor-induced osteolysis, malignant bone disease, chorioallantoic membrane assay
MeSH terms: Zoledronic Acid, Pamidronate, Cell Adhesion, Cell Cycle, Cell Movement, Cells, Cultured, Chemotaxis, Chorion, Diphosphonates, Endothelium, Vascular, Growth Substances, Humans, Imidazoles, Lymphokines, Muscle, Smooth, Vascular, Fibroblast Growth Factor 2, Endothelial Growth Factors, Apoptosis, Image Cytometry, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks